Gedeptin is a Gene Therapy owned by GeoVax Labs, and is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing.
Gedeptin, Ad/PNP containing the E. coli PNP gene is injected into the tumor where it infects the tumor cell and produces the E. coli PNP enzyme. Upon administration, fludarabine phosphate is dephosphorylated to 2-fluoro-ara-A by plasma enzymes. F-araA diffuses into the tumor cell where it is converted to 2-fluoroadenine by the E. coli PNP enzyme and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. It kills the tumor cell in which it was originally made and also destroys neighboring tumor cells not infected with the vector.
The revenue for Gedeptin is expected to reach a total of $37m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Gedeptin NPV Report.
Gedeptin was originated by Southern Research Institute and UAB Minority Health and Health Equity Research Center and is currently owned by GeoVax Labs.
Gedeptin (Ad/PNP-F-araAMP) is under development for the treatment of oropharyngeal cancer and head and neck cancer. Ad/PNP is administered intratumorally with co-administration of fludarabine phosphate intravenously. Adenovirus/PNP is an adenovirus loaded with E. coli purine nucleoside phosphorylase (E. coli PNP). The drug candidate is developed based on PNP Technology.
GeoVax Labs Overview
GeoVax Labs (GeoVax) is a biotechnology company that develops immunotherapies and vaccines against cancers and various infectious diseases. GeoVax develops vaccines using its novel patented Modified Vaccinia Ankara-Virus like Particle (MVA-VLP) vector vaccine platform focused on therapy areas such as infectious diseases like HIV, Lassa fever, Ebola, Zika virus, malaria, Hepatitis B, coronavirus, and cancers related to solid tumors and HPV-associated head and neck cancer. The company has partnerships for preclinical and clinical testing with various government, academic and corporate entities, including the Centers for Disease Control and Prevention (CDC), Leidos Inc, Scripps Research Institute, and Emory University. GeoVax is headquartered in Smyrna, Georgia, the US.
The company reported revenues of (US Dollars) US$0.4 million for the fiscal year ended December 2021 (FY2021), a decrease of 78.8% over FY2020. The operating loss of the company was US$18.6 million in FY2021, compared to an operating loss of US$2.8 million in FY2020. The net loss of the company was US$18.6 million in FY2021, compared to a net loss of US$3 million in FY2020.
Quick View – Gedeptin
|Highest Development Stage|